BurnsAdler, Three Rivers sales and marketing update

Three Rivers granted BurnsAdler exclusive rights to market Infergen interferon alphacon-1 in Brazil and Chile to treat HCV. Three Rivers has rights to the drug in the U.S. and Canada from Valeant Pha...